Just had a quick look at CMP. What I can see is $36mill reveune...

Just had a quick look at CMP. What I can see is $36mill reveune but a profit for the year of only $100K. Suggested in its preliminary report is that sales in its major market is declining. CMP was a $1+ stock in early 2000. Now at 14.5c there's obviously a bit of history that's derailed this stock. So maybe CMP is worth more than its current $20mill I don't know as I'm not sure what plans CMP have to further increase revenues and reduce costs so that it can make a profit.

KSX on the other hand is a newly listed company and is just on the cusp of moving from developer to producer. The product range they have is unique to the market and will (hopefully) alter the way asthma is controlled in the future. They are targeting up front the lucrative US and European markets and have a number of influential hospitals trialling their product at the moment with some promising results already.

As for calculating marketcaps it is probably not fair to include the options right at this pointin the marketcap since they don't expire until August 2008 and are not guaranteed to be exercised. On top of this the exercise of these options would attract around $13mill into the coffers meaning there should be no need for KSX to go back to market to achieve their plan.

At almost $60mill KSX is certainly factoring in some near-term success but traditionally companies in the bio sector do attract decent premiums and I think the current shareprice does indicate the excitement about the future.

Remember the market is all about momentum. Obviously CMP doesn't currently have the momentum for whatever reason.

To really guage what KSX has, I recommend reading up on some of the announcements which clearly state the business plan and the goals achieved. Personally I'm fairly impressed with their progress.